The attempt of control of glioma dissemination lesions in Vandetanib
| Project/Area Number |
24592162
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Tottori University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KAMBE Atsushi 鳥取大学, 医学部, 助教 (70348283)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2012: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Keywords | Vandetanib / グリオーマ / 播種 / Glioblastoma / MGMT |
|---|
| Outline of Final Research Achievements |
We have investigated the effects of tumor suppression and the control of dissemination with EGFR/VEGF dual inhibitor, Vandetanib in glioma cells. Vandetanib indicated the suppression of tumor proliferation and invasion and induced apoptosis in rat C6 glioma cells using several in vitro studies. Same tendency was recognized in human glioblastoma cell lines, but significant suppression was not obtained in MGMT-positive human glioblastoma cell lines. We transfected MGMT siRNA into the MGMT-positive cell lines and performed same experiments. We could confirm the improvement of reactivity of Vandetanib treatment, but not obtain the significant results. It is necessary to do further reseach to perform the experiment with rat dissemination models.
|
Report
(4 results)
Research Products
(1 results)
